A Phase 1 interventional study of ABBV-701 and Placebo in Healthy Volunteer, sponsored by AbbVie. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
For Japanese Participants:
--Participant must be first or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health and maintain a typical Japanese lifestyle, including consuming a typical Japanese diet.
Han Chinese Participants:
--Participant must be first or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health and maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.
Exclusion Criteria:
Participants will receive a single dose of either ABBV-701 Dose A or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose B or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose C or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose D or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose E or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose E or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose E or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose C or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose E or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose F or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose F or placebo.
Drug: ABBV-701 · Drug: Placebo
Participants will receive a single dose of either ABBV-701 Dose F or placebo.
Drug: ABBV-701 · Drug: Placebo
Subcutaneous
Subcutaneous
IV Infusion
IV infusion
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 47 weeks
Maximum Plasma Concentration (Cmax) of ABBV-701
Cmax of ABBV-701
Time frame: Up to approximately 47 weeks
Time to Cmax (Tmax) of ABBV-701
Tmax of ABBV-701
Time frame: Up to approximately 47 weeks
Apparent terminal phase elimination rate constant (β) of ABBV-701
(β) of ABBV-701
Time frame: Up to approximately 47 weeks
Terminal Phase Elimination Half-Life (t1/2) of ABBV-701
(t1/2) of ABBV-701
Time frame: Up to approximately 47 weeks
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-701
AUCt of ABBV-701
Time frame: Up to approximately 47 weeks
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-701
AUCinf of ABBV-701
Time frame: Up to approximately 47 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie